The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
Open accessAbstract
One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs.We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs.Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs.Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice.Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19.We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.Nonstandard abbreviations used: indoleamine 2,3-dioxygenase (IDO); 1-methyl-D-tryptophan (1MT); mixed leukocyte reaction (MLR); plasmacytoid DC (pDC); regulatory T cell (Treg); T cell receptor (TCR); tumor-draining LN (TDLN). Conflict of interest:The authors have declared that no conflict of interest exists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, heightened activity of the Trp-Kyn-AhR pathway has been linked to impairment of antitumor immunity and tumor growth (16,17).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
T cell receptor antagonist peptides induce positive selection.
Hogquist, K., Jameson, S., Heath, W., Howard, J. L., Bevan, M., & Carbone, F. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 3,252
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,162
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,820
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I. E., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,640
Self-citationModulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204
Commitment to the B-lymphoid lineage depends on the transcription factor Pax5
Nutt, S. L., Heavey, B., Rolink, A. G., & Busslinger, M. (1999) · Nature · doi:10.1038/44076 · Cited by 1,179
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y.-C., Golumbek, P. T., Ahmadzadeh, M., Jaffee, E. M., Pardoll, D. M., & Levitsky, H. I. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,159
Flagged first, then by citations
Research works printed but not linked: 2
- Cuenca, 2003, Cancer Res., 63, 9007
- Almand, 2000, Clin. Cancer Res., 6, 1755
Cited by
Sorted by citations
Items 401–500 of 877
Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase
Noh, K. T., Chae, S. H., Chun, S. H., Jung, I. D., Kang, H. K., & Park, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.093 · Cited by 42
Karrich, J. J., Jachimowski, L. C. M., Nagasawa, M., Kamp, A. M., Balzarolo, M., Wolkers, M. C., Uíttenbogaart, C. H., van Ham, S. M., & Blom, B. (2013) · Blood · doi:10.1182/blood-2012-08-452995 · Cited by 47
Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allografts
Dürr, S., & Kindler, V. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0712347 · Cited by 45
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma
de Jong, R. A., Kema, I. P., Boerma, A., Boezen, H. M., van der Want, J. J. L., Gooden, M. J. M., Hollema, H., & Nijman, H. W. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.05.034 · Cited by 44
HPV vaccines: the beginning of the end for cervical cancer
Leggatt, G. R., & Frazer, I. H. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.004 · Cited by 43
The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
Andersen, M. H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1234-4 · Cited by 41
B Cell–Intrinsic IDO1 Regulates Humoral Immunity to T Cell–Independent Antigens
Shinde, R. S., Shimoda, M., Chaudhary, K., Liu, H., Mohamed, E. T., Bradley, J., Kandala, S., Li, X., Liu, K., & McGaha, T. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402854 · Cited by 41
Ipilimumab: From Preclinical Development to Future Clinical Perspectives in Melanoma
Letendre, P., Monga, V., Milhem, M. M., & Zakharia, Y. (2016) · Future Oncology · doi:10.2217/fon-2016-0385 · Cited by 43
Wu, Y. K., Xu, T., Liu, J., Ding, K., & Xu, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.061 · Cited by 41
Adinew, G. M., Taka, E., Mochona, B., Badisa, R. B., MAZZIO, E. A., Elhag, R. I., & Soliman, K. F. A. (2021) · Nutrients · doi:10.3390/nu14010079 · Cited by 42
Iachininoto, M. G., Nuzzolo, E. R., Bonanno, G., Mariotti, A., Procoli, A., Locatelli, F., CRISTOFARO, R. D., & Rutella, S. (2013) · Molecules · doi:10.3390/molecules180910132 · Cited by 41
Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer
Ino, K. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3283409c79 · Cited by 41
Rond, S. L., González, Á., Gonzalez, A. S. L., Carosella, E. D., & Rouas‐Freiss, N. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02224.x · Cited by 44
He, Y., Wang, H., Zeng, J., Fang, X., Chen, H., Du, J., & Yang, X. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.07.028 · Cited by 40
Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma
Monti, M., Consoli, F., Vescovi, R., Bugatti, M., & Vermi, W. (2020) · Cells · doi:10.3390/cells9020417 · Cited by 41
Tryptophan metabolism and immune regulation in the human placenta
Silvano, A., Seravalli, V., Strambi, N., Cecchi, M., Tartarotti, E., Parenti, A., & Tommaso, M. D. (2021) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2021.103361 · Cited by 41
Immunotherapy and immunoescape in colorectal cancer
Mazzolini, G. D. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i44.5822 · Cited by 40
STAT3: a potential therapeutic target in dendritic cells for the induction of transplant tolerance
Barton, B. E. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.3.459 · Cited by 40
Immunotherapy in acute myeloid leukemia
Grosso, D. A., Hess, R., & Weiss, M. A. (2015) · Cancer · doi:10.1002/cncr.29378 · Cited by 39
Accumulation of plasmacytoid DC: Roles in disease pathogenesis and targets for immunotherapy
Swiecki, M. K., & Colonna, M. (2010) · European Journal of Immunology · doi:10.1002/eji.201040602 · Cited by 41
Ito, H., Ando, T., Arioka, Y., Saito, K., & Seishima, M. (2014) · Immunology · doi:10.1111/imm.12413 · Cited by 39
Keswani, T., Sarkar, S., Sengupta, A., & Bhattacharyya, A. (2016) · Cytokine · doi:10.1016/j.cyto.2016.08.034 · Cited by 39
Integration of Nano drug-delivery System With Cancer Immunotherapy
Nakamura, T., & Harashima, H. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0071 · Cited by 39
The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates
Mohamed, E. T., Al-Khami, A. A., & Rodrı́guez, P. C. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0001-7 · Cited by 39
Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma
Penny, H. L., Sieow, J. L., Gun, S. Y., Lau, M. C., Lee, B. T. K., Tan, J., Phua, C., Toh, F., Nga, Y., Yeap, W. H., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126350 · Cited by 39
Yuasa, H. J., & Ball, H. J. (2015) · Journal of Experimental Zoology Part B Molecular and Developmental Evolution · doi:10.1002/jez.b.22608 · Cited by 39
Junker, N., Andersen, M. H., Wenandy, L., Dombernowsky, S. L., Kiss, K., Sørensen, C. H., Therkildsen, M. H., von Buchwald, C., Andersen, E., Straten, P. T., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2011.563291 · Cited by 39
Möller, I., Michel, K., Frech, N., Burger, M., Pfeifer, D., Frommolt, P., Veelken, H., & Thomas-Kaskel, A. K. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177d9e5 · Cited by 41
Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism
Rosa, V. D., Rella, F. D., Giacomo, A. D., & Matarese, G. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.001 · Cited by 38
Antimicrobial and immunoregulatory effector mechanisms in human endothelial cells
Schmidt, S. K., Heseler, K., Spekker, K., MacKenzie, C. R., & Däubener, W. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-04-0250 · Cited by 39
Indoleamine 2,3‐Dioxygenase Expression and Regulation in Chronic Periodontitis
Nisapakultorn, K., Makrudthong, J., Sa‐Ard‐Iam, N., Rerkyen, P., Mahanonda, R., & Takikawa, O. (2008) · Journal of Periodontology · doi:10.1902/jop.2009.080315 · Cited by 38
Zardoya-Laguardia, P., Blaschitz, A., Hirschmugl, B., Lang, I., Herzog, S. A., Nikitina, L., Gauster, M., Haeusler, M. C. H., Cervar-Zivkovic, M., Karpf, E., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23896-0 · Cited by 38
Zhang, Y., Fu, J., Shi, Y., Peng, S., Cai, Y., Zhan, X., Song, N., Liu, Y., Wang, Z., Yu, Y., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31588 · Cited by 37
Brincks, E. L., Adams, J., Wang, L., Turner, B. A., Marcinowicz, A., Ke, J., Essmann, M., Mautino, L. M., Allen, C. V., Kumar, S., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27646 · Cited by 37
Malaria parasite induces tryptophan-related immune suppression in mice
Tetsutani, K., TO, H., Torii, M., Hisaeda, H., & Himeno, K. (2007) · Parasitology · doi:10.1017/s0031182007002326 · Cited by 37
Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies
Yang, J. Y., Shangguan, J., Eresen, A., Li, Y., Wang, J., & Zhang, Z. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152691 · Cited by 36
Bouchlaka, M. N., Sckisel, G. D., Wilkins, D. E. C., Maverakis, E., Monjazeb, A. M., Fung, M. A., Welniak, L., Redelman, D. D., Fuchs, A., Evrensel, C. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048049 · Cited by 37
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
Agarwala, S. S., & Ribas, A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dcd260 · Cited by 36
Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds
Pucchio, T. D., Danese, S., CRISTOFARO, R. D., & Rutella, S. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903512974 · Cited by 37
Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy
Ogura, J., Miyauchi, S., Shimono, K., Yang, S., Gonchigar, S. J., Ganapathy, V., & Bhutia, Y. D. (2017) · Biochemical Journal · doi:10.1042/bcj20170583 · Cited by 37
Barreto, F. S., Filho, A. J. M. C., Araújo, M. C., de Moraes, M. O., de Moraes, M. E. A., Maes, M. H. J., de Lucena, D. F., & Macêdo, D. S. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000384 · Cited by 37
Xue, Z., Sjögren, H. O., Salford, L. G., & Widegren, B. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.01.006 · Cited by 36
Tanaka, K., Ishikawa, S., Matsui, Y., Tamesada, M., Harashima, N., & Harada, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2010.01841.x · Cited by 36
Sun, J., Yu, J., Li, H., Yang, L., Wei, F., Yu, W., Liu, J., & Ren, X. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-82 · Cited by 36
Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy
Sioud, M. (2019) · Cancers · doi:10.3390/cancers11020176 · Cited by 37
The versatile plasmacytoid dendritic cell: Function, heterogeneity, and plasticity
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.10.002 · Cited by 35
A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells
Weng, T., Huang, S.-S., Yen, M., Lin, C., Chen, Y., Lin, C.-M., Chen, W.-C., Wang, C., Chang, J., & Lai, M.-D. (2013) · Molecular Therapy · doi:10.1038/mt.2013.236 · Cited by 35
Pitfalls on the roadmap to γδ T cell-based cancer immunotherapies
Martinet, L., Poupot, R., & Fournié, J. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.03.011 · Cited by 38
Yamamoto, R., Yamamoto, Y., Imai, S., Fukutomi, R., Ozawa, Y., Abe, M., Matuo, Y., & Saito, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088789 · Cited by 35
Poormasjedi‐Meibod, M., Jalili, R. B., Hosseini‐Tabatabaei, A., Hartwell, R., & Ghahary, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071044 · Cited by 35
Yang, H., Yen, M., Lin, C., Lin, C.-M., Chen, Y., Weng, T., Huang, T., Wu, C., & Lai, M.-D. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010001 · Cited by 34
Aldajani, W. A., Salazar, F., Sewell, H. F., Knox, A. J., & Ghaemmaghami, A. M. (2016) · Oncotarget · doi:10.18632/oncotarget.11586 · Cited by 34
Huang, T., Yen, M., Lin, C., Weng, T., Chen, Y., Lin, C., & Lai, M. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02094.x · Cited by 34
Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Horna, P., & Sotomayor, E. M. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780006940 · Cited by 34
Draghiciu, O., Nijman, H. W., & Daemen, T. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/439053 · Cited by 35
Erratum: Recent Advances in Dendritic Cell Biology
Adams, S., O’Neill, D. W., & Bhardwaj, N. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-4086-2 · Cited by 34
Targeting amino acid-metabolizing enzymes for cancer immunotherapy
Grobben, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440269 · Cited by 35
Immunotherapy in Acute Myeloid Leukemia
Arpinati, M., & Curti, A. (2013) · Immunotherapy · doi:10.2217/imt.13.152 · Cited by 33
Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
Rajani, K. R., Carlstrom, L. P., Parney, I. F., Johnson, A. J., Warrington, A. E., & Burns, T. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00656 · Cited by 33
Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells
Ozawa, Y., Yamamuro, S., Sano, E., Tatsuoka, J., Hanashima, Y., Yoshimura, S., Sumi, K., Hara, H., Nakayama, T., Suzuki, Y., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.01.148 · Cited by 34
Shadbad, M. A., Hajiasgharzadeh, K., Derakhshani, A., Silvestris, N., Baghbanzadeh, A., Racanelli, V., & Baradaran, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623639 · Cited by 33
El-kholy, N. M., Sallam, M. M., Ahmed, M. B., Sallam, R. M., Asfour, I. A., Hammouda, J. A., Habib, H., & Abu-Zahra, F. (2010) · Medical Oncology · doi:10.1007/s12032-010-9459-6 · Cited by 33
Berthon, C., Fontenay, M., Corm, S., Briche, I., Allorge, D., Hennart, B., Lhermitte, M., & Quesnel, B. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.02.001 · Cited by 34
Paveglio, S. A., Allard, J. B., Hodgkins, S. R., Ather, J. L., Bevelander, M., Campbell, J. M., Leclair, L., McCarthy, S. M., van der Vliet, A., Suratt, B. T., et al. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0167oc · Cited by 33
Zhang, Y., Zhang, J., Zhao, S., Xu, Y., Huang, Y., Liu, S., Su, P., Wang, C., Li, Y., Li, H., et al. (2024) · Theranostics · doi:10.7150/thno.99112 · Cited by 32
Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy
Liu, H., Lu, Y., Zong, J., Zhang, B., Li, X., Qi, H., Yu, T., & Li, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02913-7 · Cited by 34
The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma
Jia, H., Ren, W., Feng, Y., Wei, T., Guo, M., Guo, J., Zhao, J., Song, X., Wang, M., Zhao, T., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4473 · Cited by 32
Small molecule drugs with immunomodulatory effects in cancer
Murphy, A. G., & Zheng, L. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1057363 · Cited by 33
Peripheral tolerance in CD8+ T cells
Srinivasan, M., & Frauwirth, K. A. (2009) · Cytokine · doi:10.1016/j.cyto.2009.01.010 · Cited by 32
Metz, R. A., DuHadaway, J. B., Rust, S., Munn, D. H., Muller, A. J., Mautino, M. R., & Prendergast, G. C. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0185 · Cited by 32
Self-citationJohnson, T. S., McGaha, T. L., & Munn, D. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_7 · Cited by 32
Self-citationGigley, J. P., & Khan, I. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020838 · Cited by 31
Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases
Tan, P., & Bharath, A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903018940 · Cited by 31
Salter, R. D., & Shurin, M. R. (2009) · Springer eBooks · doi:10.1007/978-0-387-88611-4 · Cited by 32
IDO Targeting in Sarcoma: Biological and Clinical Implications
Nafia, I., Toulmonde, M., Bortolotto, D., Chaïbi, A., Bodet, D., Rey, C., Velasco, V., Larmonier, C. B., Cerf, L., Adam, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00274 · Cited by 30
Mangaonkar, A. A., Reichard, K. K., Binder, M., Coltro, G., Lasho, T. L., Carr, R. M., Chiu, A., Negron, V. C., Hefazi, M., Anagnostou, T., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002415 · Cited by 30
Cherney, E. C., Zhang, L., Nara, S. J., Zhu, X., Gullo-Brown, J. L., Maley, D., Lin, T.-A., Hunt, J. T., Huang, C., Yang, Z., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00668 · Cited by 30
Haghighitalab, A., Matin, M. M., Amin, A., Minaee, S., Bidkhori, H. R., Doeppner, T. R., & Bahrami, A. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-87153-7 · Cited by 33
Heeren, A. M., Rotman, J., Samuels, S., Zijlmans, H. J. M. A. A., Fons, G., de Vijver, K. K. V., Bleeker, M. C. G., Kenter, G. G., Jordanova, E. J., & de Gruijl, T. D. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003623 · Cited by 30
Takamori, S., Ishikawa, S., Suzuki, J., Oizumi, H., Uchida, T., Ueda, S., Edamatsu, K., Iino, M., & Sugimoto, M. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14282 · Cited by 30
Biswas, P., Dai, Y., & Stuehr, D. J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.01.008 · Cited by 31
Godin-Ethier, J., Hanafi, L., Duvignaud, J., Leclerc, D., & Lapointe, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.08.017 · Cited by 32
Role of IDO in Organ Transplantation: Promises and Difficulties
Löb, S., & Königsrainer, A. (2009) · International Reviews of Immunology · doi:10.1080/08830180902989119 · Cited by 32
Sioud, M. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02326.x · Cited by 30
Jalili, R. B., Forouzandeh, F., Moeenrezakhanlou, A., Rayat, G. R., Rajotte, R. V., Uludağ, H., & Ghahary, A. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080539 · Cited by 30
Lung dendritic cells and the inflammatory response
Grayson, M. H. (2006) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)61061-7 · Cited by 30
Serotonin, Kynurenine, and Indole Pathways of Tryptophan Metabolism in Humans in Health and Disease
Holeček, M. (2026) · Nutrients · doi:10.3390/nu18030507 · Cited by 30
Norouzian, M., Mehdipour, F., Balouchi-Anaraki, S., Ashraf, M. J., Khademi, B., & Ghaderi, A. A. (2019) · Head and Neck Pathology · doi:10.1007/s12105-019-01095-1 · Cited by 29
Pearson, J. T., Siu, S., Meininger, D. P., Wienkers, L. C., & Rock, D. A. (2010) · Biochemistry · doi:10.1021/bi100022c · Cited by 29
Zeng, J., Cai, S., Yi, Y., He, Y., Wang, Z., Jiang, G., Li, X., & Du, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2476 · Cited by 29
Huang, B., Mao, C.-P., Peng, S., Hung, C., & Wu, T. ‐. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.059 · Cited by 29
Neuronal localization of indoleamine 2,3-dioxygenase in mice
Roy, E. J., Takikawa, O., Kranz, D. M., Brown, A. R., & Thomas, D. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.07.010 · Cited by 29
Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications
Li, W., Yu, C., Zhang, X., Gu, Y., He, X., Xu, R., Xu, J. F., Yu, G., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00300-8 · Cited by 28
Cuevas, E. S., Ouaguia, L., Mouret, S., Charles, J., de Fraipont, F., Manches, O., Valladeau‐Guilemond, J., Bendriss‐Vermare, N., Chaperot, L., & Aspord, C. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1190 · Cited by 32
Forouzandeh, F., Jalili, R. B., Germain, M., Duronio, V., & Ghahary, A. (2008) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2008.00377.x · Cited by 28
T Cell Regulatory Plasmacytoid Dendritic Cells Expressing Indoleamine 2,3 Dioxygenase
Kahler, D. J., & Mellor, A. L. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-71029-5_8 · Cited by 29
Self-citationClinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantation
Brandacher, G., Margreiter, R., & Fuchs, D. (2008) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3282f3df26 · Cited by 28
Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!
Castro, M. G., Baker, G. J., & Lowenstein, P. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0820 · Cited by 27
Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
Passiglia, F., Reale, M. L., Cetoretta, V., & Novello, S. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s253581 · Cited by 27
Mitchell, D. K., Shireman, J. M., Potchanant, E. A. S., Lara-Velazquez, M. A., & Dey, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.716947 · Cited by 27
Metadata
- Authors
- Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L.
- Affiliations
- Augusta University (US)
- University of South Florida (US)
- Corresponding author
- Munn, David H.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2004-07-15
- Volume
- 114
- Issue
- 2
- Pages
- 280-290
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2143565660
- Cited by
- 852
- References
- 85
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 32 · 2021: 37 · 2020: 34 · 2019: 29 · 2018: 31 · 2017: 40 · 2016: 27 · 2015: 45 · 2014: 38 · 2013: 53 · 2012: 39
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Carlos and Marguerite Mason Trust
- National Institutes of Health
- National Cancer Institute (R01CA096651, R01 CA103220)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD041187)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- indoleamine 2,3-dioxygenase, plasmacytoid dendritic cells, tumor-draining lymph nodes, immunosuppression, T cell anergy, tumor antigen presentation, CD19, 1-methyl-D-tryptophan, antitumor immunity, regulatory T cells, mixed lymphocyte reaction
- MeSH terms
- Animals, Antigen-Presenting Cells, Dendritic Cells, Female, Humans, Immunosuppression Therapy, Lymph Nodes, Lymphocyte Activation, Mice, Inbred Strains, Neoplasms, Random Allocation, T-Lymphocytes, Tryptophan Oxygenase, Survival Rate, Mice, Knockout, Antigens, CD19, Adoptive Transfer, CD11c Antigen, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
